Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 7 of 7 for “"Cyclin-Dependent Kinase 4"”.
-
Impact of Cyclin-Dependent Kinase 4 and 6 Inhibitors on Chemotherapy Utilization and Overall Survival in Women with HR+/HER2– Metastatic Breast Cancer in the United States
… lines. In this study, we explored the impact of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy class, introduced in 2015, on early chemotherapy utilization in an older population of patients with HR+/HER2– MBC in the United States (US). Methods: Using an interrupted time series …
-
Impact of delta-tocotrienol on human melanoma cell proliferation
… melanoma cells. d-δ-tocotrienol induced dose-dependent suppression of the cell proliferation following 72 h incubation in 96-well plates with 50% inhibitory concentrations (IC50) of 37.5 ± 1.4 (A2058) and 22.3 ± 1.8 (A375) μmol/L, respectively. d-δ-tocotrienol-mediated cell cycle arrest at the …
-
Overcoming Resistance to CDK4/6-targeted Therapy Using JAK2/STAT3 Inhibitor in Triple-Negative Breast Cancer
… in high rates of recurrence and metastasis. Cyclin-dependent kinase 4 and 6 (CDK4/6) are major cell cycle regulators that control G1 to S phase transition and aberrant hyperactivation of the CDK4/6 pathway results in uncontrolled cell proliferation. Although three CDK4/6 inhibitors (CDK4/6is) …
-
Drivers of melanoma susceptibility
… by pathogenetic variants in genes such as cyclin-dependent kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase 4 (CDK4), breast cancer 2 (BRCA2), BRCA1-associated protein-1 (BAP1) and in the promoter of the telomerase reverse transcriptase (TERT). However, about 50% of all familial …
-
Androgen Receptor: A Complex Therapeutic Target in Breast Cancer
… breast cancer is treated with hormonal and cyclin-dependent kinase 4/6 targeted therapies, the cancer relapses and becomes resistant to the treatment options. Androgen receptor (AR) that is expressed in over 90\% of ER-positive breast cancer and in 20\% of TNBC is a pharmacologically …
-
Targeting Cyclin Dependent Kinases 4/6 Activity in Pancreatic Ductal Adenocarcinoma
Pages vi-xiii are incorrectly numbered as pages v-xii.
-
Development of less toxic analogues of fascaplysin as novel therapeutic agents for the treatment of cancer
Cyclin-dependent kinase 4 (Cdk4) represents a crucially important target for the treatment of cancer because most human cancers are characterised by over-expression of its activating partner cyclin Dl (product of an oncogene), loss of the natural Cdk4 specific inhibitor p 16 INK4A or mutation in …